CLL/MCL Coverage from Every Angle
Editor:
Jeremy S. Abramson, MD, MMSc
Advertisement
Advertisement

Videos

Matthew S. Davids, MD, MMSc, on TP53-Aberrant CLL: Combination of Acalabrutinib, Venetoclax, and Obinutuzumab

Barbara Eichhorst, MD, on Clinical Implications of New Findings on Venetoclax, Obinutuzumab, and Chemoimmunotherapy for CLL

William G. Wierda, MD, PhD, on CLL/SLL: 3-Year Follow-up Data on Ibrutinib Plus Venetoclax

Jennifer A. Woyach, MD, on Using MRD to Treat CLL/SLL

Alexey V. Danilov, MD, PhD, on Ibrutinib, Acalabrutinib, and Other Agents for CLL: Expert Perspective on Benefits and Risks

Arnon P. Kater, MD, PhD, on Treatment Advantages With Ibrutinib Plus Venetoclax for Older Patients With CLL

Paolo Ghia, MD, PhD, on Clinical Implications of Treating CLL/SLL With Ibrutinib Plus Venetoclax

Jennifer R. Brown, MD, PhD, Clinical Strategies for Selecting Treatment in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Matthew S. Davids, MD, on Clinical Implications of New Data on Newer CLL Therapies

Matthew S. Davids, MD, on Ibrutinib and Umbralisib in CLL or Mantle Cell Lymphoma

Matthew S. Davids, MD, on Sequence of Administration of Ibrutinib Plus Obinutuzumab for CLL

Steven P. Treon, MD, PhD, on Treating COVID-19–Related Pulmonary Failure by Targeting BTK With Ibrutinib

John C. Byrd, MD, on Long-Term Follow-up of Acalabrutinib Treatment in CLL/SLL

Nitin Jain, MD, on Implications of Using Ibrutinib Plus Venetoclax in the Front-Line Setting and Beyond

Jennifer Crombie, MD, on the Challenges of Using Duvelisib and Venetoclax in Patients With Relapsed or Refractory CLL/SLL

Tait D. Shanafelt, MD, on Comparing Toxicities of New and Standard Treatments for CLL

Jeff P. Sharman, MD, on Clinical Pearls on Treatments Containing Acalabrutinib

Laura Zitella on Helping Patients With Hematologic Malignancies Manage Symptoms: Advice From an AP on the Front Lines

Nitin Jain, MD, on Evolving Treatment Paradigms

Nitin Jain, MD, on Targeted Treatments and Tumor-Lysis Syndrome

Jennifer R. Brown, MD, PhD, on BTK Inhibitors: Zanubrutinib, Ibrutinib, Acalabrutinib in CLL/SLL

Jennifer R. Brown, MD, PhD, on Using Venetoclax and Rituximab in Chronic Lymphocytic Leukemia

Jennifer R. Brown, MD, PhD, on Treating CLL/SLL With Ibrutinib: Findings From the RESONATE Trial

Jennifer R. Brown, MD, PhD, on Treating CLL With the Novel Immunotherapy KTE-X19

Jennifer R. Brown, MD, PhD, on CLL: The Role of Genomic Sequencing

Ian W. Flinn, MD, PhD, on Chronic Lymphocytic Leukemia: Early-Phase Research on Immunotherapy

Kerry A. Rogers, MD, on Chronic Lymphocytic Leukemia: Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed or Refractory Disease

William G. Wierda, MD, PhD, on Using Venetoclax in CLL

Jennifer R. Brown, MD, PhD, on Chronic Lymphocytic Leukemia: Treatment Trends

Ian W. Flinn, MD, PhD, on CLL/SLL: Effect of Dose Modifications on Response to Duvelisib

William G. Wierda, MD, PhD, on Clinical Implications of Experimental CAR T-Cell Treatment in Relapsed/Refractory CLL/SLL

The JNCCN Spotlight

Copyright © 2025 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.